Chester County News and Community Website
WEST CONSHOHOCKEN, PA — PRM Pharma, LLC has announced the availability of HEMICLOR® (12.5 mg chlorthalidone tablets), the first FDA-approved low-dose formulation of chlorthalidone for the treatment of hypertension in …
PRM Pharma Launches HEMICLOR, First FDA-Approved Low-Dose Chlorthalidone Tablet Read More
NEW HOPE, PA — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) has presented key clinical insights into its atrioventricular interval modulation (AVIM) therapy for high-risk hypertension during the Congenital, Structural, and …
Orchestra BioMed Highlights AVIM Therapy’s Potential at CSI 2025 Meeting Read More
RADNOR, PA — Mineralys Therapeutics, Inc. (Nasdaq: MLYS) has announced detailed results from its pivotal Phase 3 Launch-HTN trial, showcasing the efficacy and safety of lorundrostat for patients with uncontrolled …
Mineralys Therapeutics Reveals Promising Phase 3 Results for Hypertension Drug Lorundrostat Read More RADNOR, PA — Mineralys Therapeutics, Inc. (Nasdaq: MLYS) has announced that the findings from its pivotal Phase 3 Launch-HTN trial on lorundrostat, a novel medication targeting uncontrolled hypertension (uHTN) and …
Mineralys Therapeutics to Present Phase 3 Data on Lorundrostat at European Hypertension Meeting Read More WEST CONSHOHOCKEN, PA — The U.S. Food and Drug Administration (FDA) has approved HemiClor, a 12.5 mg chlorthalidone tablet developed by PRM Pharma, LLC, for the treatment of hypertension in …
FDA Approves Low-Dose Hypertension Treatment HemiClor Read More RADNOR, PA — Mineralys Therapeutics, Inc. (Nasdaq: MLYS) announced the publication of groundbreaking Phase 2 trial results for its medication lorundrostat in the New England Journal of Medicine (NEJM). The …
Mineralys Therapeutics Publishes Pivotal Hypertension Trial Results in NEJM Read More
RADNOR, PA — Idorsia Pharmaceuticals U.S. Inc. has announced the availability of TRYVIO™ (aprocitentan) in the United States for adults suffering from hypertension. This new medication is intended to be used …
New Hypertension Treatment TRYVIO Now Available in the U.S. Read More RADNOR, PA — Mineralys Therapeutics, Inc. (Nasdaq: MLYS) announced the swift completion of participant enrollment in its Launch-HTN trial, a critical component of its pivotal program investigating lorundrostat for the …
Mineralys Therapeutics Completes Enrollment Ahead of Schedule in Pivotal Hypertension Trial Read More RADNOR, PA — Mineralys Therapeutics, Inc. (Nasdaq: MLYS) has announced an upcoming virtual Key Opinion Leader (KOL) event scheduled for Wednesday, October 30, 2024, at 10:00 AM ET. This event will …
Mineralys Therapeutics to Host Virtual Event on Hypertension Treatment Advances Read More RADNOR, PA — Mineralys Therapeutics, Inc. (Nasdaq: MLYS) has reached a significant milestone in its Advance-HTN trial by hitting its enrollment target of 261 participants. This pivotal trial is crucial in …
Mineralys Therapeutics Hits Enrollment Milestone in Hypertension Drug Trial Read More